These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 16785193

  • 1. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours.
    Sihto H, Franssila K, Tanner M, Vasama-Nolvi C, Sarlomo-Rikala M, Nupponen NN, Joensuu H, Isola J.
    Scand J Gastroenterol; 2006 Jul; 41(7):805-11. PubMed ID: 16785193
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M, Sobin LH, Lasota J.
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [Abstract] [Full Text] [Related]

  • 4. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J, Miettinen M.
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [Abstract] [Full Text] [Related]

  • 5. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
    Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A, Hagemeijer A, Sciot R.
    J Pathol; 2004 Apr; 202(4):430-8. PubMed ID: 15095270
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
    Du CY, Shi YQ, Zhou Y, Fu H, Zhao G.
    J Surg Oncol; 2008 Sep 01; 98(3):175-8. PubMed ID: 18618605
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High-resolution melting amplicon analysis as a method to detect c-kit and platelet-derived growth factor receptor alpha activating mutations in gastrointestinal stromal tumors.
    Holden JA, Willmore-Payne C, Coppola D, Garrett CR, Layfield LJ.
    Am J Clin Pathol; 2007 Aug 01; 128(2):230-8. PubMed ID: 17638656
    [Abstract] [Full Text] [Related]

  • 10. Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series.
    Gomes AL, Gouveia A, Capelinha AF, de la Cruz D, Silva P, Reis RM, Pimenta A, Lopes JM.
    J Clin Pathol; 2008 Feb 01; 61(2):203-8. PubMed ID: 17827398
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
    Loughrey MB, Trivett M, Beshay V, Dobrovic A, Kovalenko S, Murray W, Lade S, Turner H, McArthur GA, Zalcberg J, Waring PM.
    Histopathology; 2006 Jul 01; 49(1):52-65. PubMed ID: 16842246
    [Abstract] [Full Text] [Related]

  • 13. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
    Janeway KA, Liegl B, Harlow A, Le C, Perez-Atayde A, Kozakewich H, Corless CL, Heinrich MC, Fletcher JA.
    Cancer Res; 2007 Oct 01; 67(19):9084-8. PubMed ID: 17909012
    [Abstract] [Full Text] [Related]

  • 14. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.
    Sápi Z, Füle T, Hajdu M, Matolcsy A, Moskovszky L, Márk A, Sebestyén A, Bodoky G.
    Diagn Mol Pathol; 2011 Mar 01; 20(1):22-33. PubMed ID: 21326036
    [Abstract] [Full Text] [Related]

  • 15. [Expression and gene mutation of phospho-platelet derived growth factor receptor alpha and C-kit in gastrointestinal and extra-gastrointestinal stromal tumors].
    Tang M, Li DQ.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan 01; 11(1):80-3. PubMed ID: 18197502
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
    Andersson J, Bümming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, Odén A, Gustavsson B, Kindblom LG, Nilsson B.
    Gastroenterology; 2006 May 01; 130(6):1573-81. PubMed ID: 16697720
    [Abstract] [Full Text] [Related]

  • 18. [Status and clinical analysis of c-kit and PDGFRA mutations in the gastrointestinal stromal tumors].
    Du CY, Shi YQ, Zhou Y, Fu H, Zhao GF.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul 01; 11(4):371-5. PubMed ID: 18636362
    [Abstract] [Full Text] [Related]

  • 19. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
    Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM, Lopes JM.
    Histopathology; 2009 Jul 01; 55(1):53-62. PubMed ID: 19614767
    [Abstract] [Full Text] [Related]

  • 20. Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA.
    de Raedt T, Cools J, Debiec-Rychter M, Brems H, Mentens N, Sciot R, Himpens J, de Wever I, Schöffski P, Marynen P, Legius E.
    Gastroenterology; 2006 Dec 01; 131(6):1907-12. PubMed ID: 17087943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.